Prostate Cancer Data and Policy in Latvia
Incidence
There were 1,531 new cases of prostate cancer diagnosed in Latvia in 2020, accounting for 24.6% of all new cases of cancer in men.1 Estimated prostate cancer incidence in Latvia is 177.5 per 100,000, higher than the European average of 153.9 per 100,000.2
177.5
Latvia, new cases per 100,000, 20202
153.9
EU27 average, new cases per 100,000, 20202
Estimated prostate cancer incidence 2020
(crude rate per 100,000 population)
(crude rate per 100,000 population)
Mortality
In Latvia, the estimated mortality for prostate cancer is 46.9 per 100,000.1 As with prostate cancer incidence, mortality in Latvia is higher than the EU average of 32.1 per 100,000.1 In fact, Latvia has the fourth highest prostate cancer mortality rate in Europe, behind only Sweden, Denmark and Estonia.
46.9
Latvia, deaths per 100,000, 20201
32.1
EU27 average, deaths per 100,000, 20201
Prostate cancer mortality 2020
(crude rate per 100,000 population)
(crude rate per 100,000 population)
Survival
Prostate cancer five-year survival has improved significantly in Latvia, from 51.9% for patients diagnosed from 1995-1999, to 90.4% for those diagnosed from 2010-2014.1
90.4%
Latvia, five-year survival, 2010-141
51.9%
Latvia, five-year survival, 1995-991
Prostate cancer age-standardised 5-year net survival (%)
National policies
Latvia’s cancer plan for 2017-2020, the Improving health services in the field of oncology plan, was developed to improve the situation in primary diagnosis and treatment of the most common cancers, improve the scope and quality of existing screenings, and expand the availability of palliative care. The plan does not include specific objectives related to prostate cancer.
A new Plan for the Improvement of Health Care Services in the Field of Oncology for 2022–2024 is currently subject to public consultation. The overarching goal of the Plan is to promote the availability of people-centred and integrated health care services in oncology, while preventing premature mortality from cancer.
Clinical guidelines
Latvia has Prostate Cancer Clinical Guidelines (Prostate cancer (C61), clinical path). The recommended care pathway includes patient access to*:
Review by a multidisciplinary team
- Not included
Support from a specialist nurse
- Not included
Holistic needs assessment
- Not included
A tailored treatment plan
- Not included
Nutrition and exercise advice
- Not included
Psychological support
- Not included
Regular care reviews
- Not included
Cancer care
Access to specialists
In terms of the number of urologists per inhabitant, Latvia comes towards the lower end of the table of European countries with one urologist per 40,000 inhabitants.1 At the top end of the scale, Greece has the highest number of urologists per inhabitant with 10,000 citizens to every urologist.2
Approximate number of inhabitants per urologist - 2018*
Cost of cancer
The annual direct health cost of cancer per person in Latvia is around €57, one of the lowest in Europe.1 This is less than the European average of €154 per person.2 Whilst a number of factors contribute to improved outcomes for those affected by prostate cancer, studies have shown that those countries that invest more in cancer care tend to achieve better outcomes for patients.3
Direct health cost of cancer per person - 2018 (€)
Cancer medicines spend
€13 is spent annually on cancer medicines per capita in Latvia, the fourth lowest spender in the EU.1 For comparison, Austria tops the scale at €108, while Estonia and Greece both spend as little as €4 per capita.1
Per capita cost of cancer medicines - 2018 (€)
Organisations
Patient organisations
The main prostate cancer patient organisation in Latvia is:
Fonds Movember Latvija
https://www.movemberlatvija.lv/
References
Links to external websites are provided as a resource to the viewer. We accept no responsibility for the content or services of the linked site other than the information or other materials provided or reviewed by the LTPC expert group members
Incidence
1 WHO. International Agency for Research on Cancer. Latvia Factsheet. Accessible at https://gco.iarc.fr/today/data/factsheets/populations/428-latvia-fact-sheets.pdf (last accessed March 2022)
2 European Cancer Information System (ECIS). Estimates of cancer incidence and mortality in 2020. Accessible at https://ecis.jrc.ec.europa.eu/explorer.php?$0-0$1-All$2-All$4-1$3-34$6-0,85$5-2008,2008$7-7$CEstByCountry$X0_8-3$X0_19-AE27$X0_20-No$CEstBySexByCountry$X1_8-3$X1_19-AE27$X1_-1-1$CEstByIndiByCountry$X2_8-3$X2_19-AE27$X2_20-No$CEstRelative$X3_8-3$X3_9-AE27$X3_19-AE27$CEstByCountryTable$X4_19-AE27 (last accessed March 2022)
Chart source
European Cancer Information System (ECIS). Estimates of cancer incidence and mortality in 2020. Accessible at https://ecis.jrc.ec.europa.eu/explorer.php?$0-0$1-All$2-All$4-1$3-34$6-0,85$5-2008,2008$7-8$CEstByCountry$X0_8-3$X0_19-AE27$X0_20-No$CEstBySexByCountry$X1_8-3$X1_19-AE27$X1_-1-1$CEstByIndiByCountry$X2_8-3$X2_19-AE27$X2_20-No$CEstRelative$X3_8-3$X3_9-AE27$X3_19-AE27$CEstByCountryTable$X4_19-AE27 (last accessed March 2022)
Mortality
1 European Cancer Information System (ECIS). Estimates of cancer incidence and mortality in 2020. Accessible at https://ecis.jrc.ec.europa.eu/explorer.php?$0-0$1-All$2-All$4-1$3-34$6-0,85$5-2008,2008$7-8$CEstByCountry$X0_8-3$X0_19-AE27$X0_20-No$CEstBySexByCountry$X1_8-3$X1_19-AE27$X1_-1-1$CEstByIndiByCountry$X2_8-3$X2_19-AE27$X2_20-No$CEstRelative$X3_8-3$X3_9-AE27$X3_19-AE27$CEstByCountryTable$X4_19-AE27 (last accessed February 2022)
Chart source
European Cancer Information System (ECIS). Estimates of cancer incidence and mortality in 2020. Accessible at https://ecis.jrc.ec.europa.eu/explorer.php?$0-0$1-All$2-All$4-1$3-34$6-0,85$5-2008,2008$7-8$CEstByCountry$X0_8-3$X0_19-AE27$X0_20-No$CEstBySexByCountry$X1_8-3$X1_19-AE27$X1_-1-1$CEstByIndiByCountry$X2_8-3$X2_19-AE27$X2_20-No$CEstRelative$X3_8-3$X3_9-AE27$X3_19-AE27$CEstByCountryTable$X4_19-AE27 (last accessed March 2022)
Survival
1 Hofmarcher, T et al. Comparator Report on Cancer in Europe in 2019. IHE Report 2019:7. Accessible at https://www.efpia.eu/publications/cancer-comparator-report/cancer-types/prostate-cancer/ (last accessed March 2022)
Chart source
Hofmarcher, T et al. Comparator Report on Cancer in Europe in 2019. IHE Report 2019:7. Accessible at https://www.efpia.eu/publications/cancer-comparator-report/cancer-types/prostate-cancer/ (last accessed March 2022)
Cancer care
Access to specialists
1 European Society of Residents in Urology (ESRU). Latvia. March 2018. Accessible at https://esru.eu/?q=latvia (last accessed March 2022)
2 European Society of Residents in Urology (ESRU). Greece. March 2018. Accessible at https://esru.eu/?q=greece (last accessed March 2022)
Cost of cancer
1 Hofmarcher, T et al. Comparator Report on Cancer in Europe in 2019. IHE Report 2019:7. Accessible at https://www.efpia.eu/publications/cancer-comparator-report/cancer-types/prostate-cancer/ (last accessed March 2022)
2 Hofmarcher, T et al. Comparator Report on Cancer in Europe in 2019. IHE Report 2019:7. Accessible at https://www.efpia.eu/publications/cancer-comparator-report/cancer-types/prostate-cancer/ (last accessed March 2022) – average calculated from data included for individual countries.
3 Hofmarcher, T et al. Comparator Report on Cancer in Europe in 2019. IHE Report 2019:7.
Cancer medicines spend
1 Hofmarcher, T et al. Comparator Report on Cancer in Europe in 2019. IHE Report 2019:7. Accessible at https://www.efpia.eu/publications/cancer-comparator-report/cancer-types/prostate-cancer/ (last accessed March 2022)
Chart sources
*Different data sources were used for Belgium, Hungary, Italy, Romania and the UK, which may use data from different years. See references below. No data was found for Cyprus, Luxembourg, Malta and Slovakia.
European Society of Residents in Urology (ESRU). Countries. March 2018. Accessible at https://esru.eu/?q=countries (last accessed March 2022)
Federal Public Service of Public Health, Safety of the Food Chain and the Environment. HWF STATAN 2019 (detailed statistics). 2019. Accessible at https://organesdeconcertation.sante.belgique.be/fr/documents/hwf-statan-2019-statistiques-detaillees (last accessed March 2022)
Boszormenyi-Nagy, G. Report on urological inpatient care based on 2018 data. Urologia Hungarica. Accessible at http://urologiahungarica.hu/index.php/2020/05/12/beszamolo-az-urologiai-fekvobeteg-ellatasrol-a-2018-as-adatok-alapjan/ (last accessed March 2022)
I.Stat. Personale sanitario. Accessible at http://dati.istat.it/Index.aspx?DataSetCode=DCIS_PERS_SANIT (last accessed March 2022)
Institutul National De Statistica. Activitatea Unitatilor Sanitare in Anul 2019. 2020. Accessible at https://insse.ro/cms/sites/default/files/field/publicatii/activitatea_unitatilor_sanitare_anul_2019.pdf (last accessed March 2022)
United Nations, Population Division, Department of Economic and Social Affairs. World Population Prospects 2019. Accessible at https://population.un.org/wpp/Download/Files/1_Indicators%20(Standard)/EXCEL_FILES/1_Population/
WPP2019_POP_F01_1_TOTAL_POPULATION_BOTH_SEXES.xlsx (last accessed March 2022)
British Association of Urological Surgeons and The Specialist Advisory Committee in Urology. Workforce Report. 2018. Accessible at https://www.baus.org.uk/_userfiles/pages/files/publications/
Workforce_Report_Sep%202018%20ver%201.1.pdf (last accessed March 2022)
Hofmarcher, T et al. Comparator Report on Cancer in Europe in 2019. IHE Report 2019:7. Accessible at https://www.efpia.eu/publications/cancer-comparator-report/cancer-types/prostate-cancer/ (last accessed March 2022)
Hofmarcher, T et al. Comparator Report on Cancer in Europe in 2019. IHE Report 2019:7. Accessible at https://www.efpia.eu/publications/cancer-comparator-report/cancer-types/prostate-cancer/ (last accessed March 2022)